Showing posts with label economics. Show all posts
Showing posts with label economics. Show all posts

Monday, October 2, 2023

Gluten-Free Wheat?

Who would've thought gluten-free wheat could become a reality...



    A recent article published in July 2023 by the European Union details plans to utilize genomic techniques to alter the genome of an ingredient found in many of our delicious foods: wheat. Those with Celiac Disease and gluten-intolerance have been struck with the unfortunate loss of eating wheat-containing foods, and at an unfortunate price (almost 200% more than what the average person spends on food/groceries). For reference, gluten is a protein found in wheat, which those who are sensitive to/allergic to gluten cannot consume. Recently scientists in the EU; however, have proposed using cisgenesis -- a method to cross beneficial alleles from one plant to another -- to not only make wheat grown in the EU gluten-free, but also pesticide free as well. This is an immense step forward in the field of economic agriculture and the environmental well-being of citizens everywhere, as food for those who are gluten-free can become more affordable and levels of pesticide toxicity will slowly cease to impact those in the EU, in addition to the rest of the world who consumes their agricultural products. Cisgenesis has greater implications than just gluten-free wheat and pesticide-free plants, and as a matter of fact, this is what humans have been doing for centuries, except it has now become more mainstream due to pertinent implications in our everyday lives. 

    As someone with Celiac Disease and (unfortunately) not living in the EU, I found this article to be really promising and I am secretly hoping the U.S. starts taking some notes. I personally like this approach of utilizing genomic techniques that are not harmful like some GMOs, and don't require the introduction of chemicals into the food we consume on a daily basis. The European Union has clearly thought this decision out, and I appreciate that they have considered the economic burden of this autoimmune disease as it is not really discussed in the media. Having this representation makes those of us with Celiac more inclined to speak up and condone the improvements being made on the agricultural forefront. As I mentioned previously, the United States should truly consider implementing this in our domestic crops, especially considering how expensive gluten-free food is (for reference, try buying a $10 loaf of bread that needs to be frozen, with only 10 slices, and half of which have holes in them so they become useless anyways...doesn't sound so appealing, right?). I also believe this becomes a public health concern due to 1) the prevalence of the disease and 2) the food available and the affordability factor that comes with it. The EU is taking things in the right direction, and I can only hope that the U.S. will consider using similarly effective genomic techniques in our wheat sometime soon! 


To read up more on this topic:

1) https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/new-genomic-techniques-can-help-cut-pesticides-use-or-shield-celiac-disease-2023-07-05_en 

2) https://www.frontiersin.org/articles/10.3389/fpls.2014.00389/full

Friday, April 17, 2015

Generic Version of Copaxone, Multiple Sclerosis Drug, Is Approved

          On Thursday, the generic substitute for Copaxone has been approved by the FDA. Copaxone is a drug used for multiple sclerosis. In the last several years, the prices for drugs geared towards multiple sclerosis have tripled, even as more brand-name products appear in the market. A generic option would give a pricing edge, but this depends on the price and date it will go on sale. The price of all drugs drop about 90% when there are multiple generic options; however, since there is only one, the discount will not be as drastic. None of the drugs that treat multiple sclerosis have a generic equivalent. Multiple sclerosis is a nerve condition that causes blurred vision and difficulty walking. Teva manufacturers Copaxone, a brand name, when it usually manufactures generic drugs. Teva has used some aggressive plans to keep their wide consumer base. Teva has called and took their patients out to dinner, created a more concentrated drug to decrease the number of injections per week, and lowered the price. How Copaxone works is not clear; however, it is known that the main drug in there is made up of 4 amino acids. When the generic drug is released, some insurance companies may recommend that the patients try the generic brand before the name brand. Teva currently has a patent on Copaxone until September 1st, but the federal court invalidated it. They took their case to the Supreme Court for reevaluation, and the generic drug will have to wait in accordance to the court's descision or until September. Other companies, such as Myland and Synthon, are trying to get the approval for their generic Copaxone versions.
         I think it is great that the first generic drug for multiple sclerosis is almost available to the public. The prices for name-brand drugs are extremely pricey, and I personally always look for a generic brand. Competition will bring an economically beneficial solution for the people who really need the drug. They could the used the money save on other operations or medications.

Original: Link1
Supplemental: Link2